The BMJ launched a strategy to "walk the talk" on patient partnership three years ago.
1 Its key components include patient review of research papers, requiring authors to invite patients to help shape their educational articles, and new patient led content. (www.bmj.com.campaign/patient-partnership). We reported on progress a year ago. 2 Since then, with the help of patient authors, our patient reviewers, and patient panel members-to all of whom we owe a debt of thanks-we have continued our ambitious quest towards coproduced content. Each section of the journal now has a target for patient involvement, and we are refining a series of research projects, including an evaluation of the strategy's impact.
In some areas, progress has been slower than we would like. One is to realise our pledge to the #PatientsIncluded campaign to involve patients in all conferences we co-run and sponsor. But it is good to see that the campaign's call to include patients in all forums discussing their health and wellbeing is increasingly being heard, as the linked analysis by Chu et al shows. 3 Patients' views on being invited to the conference table vary from enthusiastic 4-6 to sceptical. 7 This is not surprising. It is hard to ensure that patient participation is more than tokenistic. Conference organisers need to model partnership from the outset, starting with appointing patients on to the committees that steer events.
Involving patients in setting research priorities has potential to reduce waste in the research enterprise, 8 and The BMJ now requires all authors submitting research papers to include a statement detailing if and how they included patients in their work.(http://www.bmj.com/about-bmj/resources-authors/articletypes/research). Eventually, we hope to adopt a policy where we will only publish clinical research that has been coproduced. Ioannidis argues that the value of research increases when patients are "savvy about science in the making and protected from biased influences." 9 This is worth noting. Pharma companies regularly invite patients to meetings, and many have patient groups to inform research and development. The imperative now is to identify and disseminate best practice so that patient involvement in drug research and development delivers outcomes that patients value. 10 11 The European Medicines Agency 12 and US Food and Drug Agency are also prioritising patient involvement and are collaborating on how best to achieve it.
Many organisations and foundations who fund research already embrace patient involvement and public engagement, including the Patient Centred Outcomes Research Institute, the National Institute for Health Research, and the Canadian Institutes for Health Research. Here too the challenge is to identify and implement meaningful partnership, and to assess its effect 13 on improving healthcare through better targeted research funding, outcomes that matter to patients, and a more patient oriented research agenda.
Patient involvement in strategies to improve the design, delivery, and quality of care has become routine in some settings, although "involvement" usually falls well short of partnership. The patient and carer advisory groups set up by UK hospitals, general practices, and the royal colleges tend to operate in the margins with an agenda primarily set by staff; and once again, evidence assessing their effect is weak. 14 The value of patient feedback is also limited since quantity of data has trumped quality. 15 A smaller and more manageable volume of higher quality data, combined with timely and personal interaction and feedback would be preferable; PatientOpinion.org.uk, an online way of giving feedback about your care to NHS trusts, is a good example.
Encouragingly, shared decision making, the cornerstone of partnership and patient centred care is beginning to show modest signs of moving from policy imperative to routine practice. 16 There is also a move towards partnership in undergraduate medical education 17 as universities respond to the General Medical Council's request for patient involvement in admissions, teaching, curriculum design, assessment, and governance.
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Employing patient leaders to drive engagement and partnership within the formal structure of the health service is the next logical step, and in July The BMJ heard from pioneer David Gilbert, who is the first patient director in the NHS. His experience at the Sussex Musculoskeletal Partnership and the response to it should surely encourage other services to follow suit.
Patients and their organisations have clear views on their role in coproducing health and wellbeing. 20 The new digital technologies, medical devices, and apps they are being encouraged to use could help advance partnership as well as promote self management. The promise of open access to fully integrated electronic health records also needs to be realised, and the conversations patients have in their online communities must be brought closer to the conversations currently conducted among health professionals. Health professionals should also give higher priority to patient partnership and patient centred care in routine clinical practice. The development of new patient oriented quality indicators to encourage and reward those who do will help. 21 Meanwhile, in the rarefied world of medical publishing, it's good to see other journals following The BMJ's lead. 22 The growing support for a new charter for journals on #PatientsIncluded 23 will, we hope, spur others to follow suit.
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